Aegle Therapeutics is developing extracellular vesicle therapy to accelerate regenerative healing while reducing or eliminating scarring. We believe that our EVs will function similar to their host stem cells and effect neuronal regeneration, angiogenesis, re-pigmentation and hair follicle growth in patients with severe wounds including burns and chronic pressure ulcers. We are also targeting the rare pediatric disease epidermolysis bullosa given the regenerative effects of EVs and their propensity to deliver critical proteins to diseased cells.
In May of 2018, Aegle announced that the U.S. Food and Drug Administration (FDA) had cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients. Aegle expects to initiate a Phase 1/2a clinical trial of AGLE-102 for the treatment of severe burn patients in late 2018.